CRVS Corvus Pharmaceuticals, Inc. Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
23:24
Jul 02
Jul 02
The tweet details the merger timeline between AbbVie and Apogee with no author position, noting that the atopic dermatitis space remains of interest to biopharma.
13:13
Jun 21
Jun 21
Buy the "hot zone" biotech names (3–9 months post positive data) as the author's historical M&A timing framework shows this is the window where acquirers with pre-committed capital execute; sector M&A wave across radiopharmaceuticals, MASH, IBD, and obesity validates the pattern is active.
MED
00:55
Jun 21
Jun 21
The tweet maps biotech M&A timing and independent name catalysts since the XBI bottom, but it is a factual research summary without explicit author positions or forward calls.
LOW
15:42
Jun 19
Jun 19
Co-mentioned as part of atopic dermatitis basket expected to benefit from the APGE M&A deal read-through; no specific thesis beyond sector lift.
MED
15:02
Jun 19
Jun 19
Buy CRVS ahead of Monday open; author sees novel mechanism undervaluation in the AtD space versus perceived winner $APGE, expecting a sharp re-rating catalyst at the open.
MED
14:34
Jun 19
Jun 19
Author reviews merger documents and identifies read-through targets for potential takeovers, but does not state personal positions or forward calls.
00:16
Jun 15
Jun 15
Named as potential public AtD takeout candidate alongside KYMR/AGPE/NKTR if BP shifts M&A focus from privates to public companies.
MED
20:04
May 26
May 26
The tweet notes upcoming data for APGE and mentions NKTR and CRVS without expressing a directional view or trade idea.
LOW
19:34
May 14
May 14
The author claims CRVS was shorted against the trend and argues NKTR should be valued at least twice its current price based on AtD alone.
HIGH
16:31
Feb 15
Feb 15
Sarcastic remark about another user's CRVS position; no author direction on CRVS.
LOW
14:24
Feb 10
Feb 10
Author cites CRVS as trading ~4x NKTR's EV despite minimal patient data and a mechanism of action carrying long-term safety risk, used as a valuation foil for NKTR.
MED
19:10
Jan 04
Jan 04
Short CRVS as author argues it faces greater competitive displacement from KYMR than injectable biologics do, implying structural vulnerability in its market position; no large dataset yet to catalyze broader awareness.
MED
About CRVS Analyst Coverage
Buzzberg tracks CRVS (Corvus Pharmaceuticals, Inc.) across 2 sources. 2 bullish vs 1 bearish calls from 2 analysts. Sentiment: predominantly bullish (8%). 12 total trade ideas tracked. Latest voices: seedy19tron, A May MD.